Abiprubart + Placebo

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sjögrens Disease

Conditions

Sjögrens Disease

Trial Timeline

Jul 17, 2024 → May 1, 2025

NCT ID

NCT06531395

About Abiprubart + Placebo

Abiprubart + Placebo is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for Sjögrens Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT06531395. Target conditions include Sjögrens Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06531395	Phase 2	Terminated	Jul 17, 2024	May 1, 2025	Sjögrens Disease

Competing Products

1 competing product in Sjögrens Disease

See all competitors

Product	Company	Stage	Hype Score
VAY736 1ml PFS + VAY736 2 ml PFS + VAY736 2ml AI	Novartis	Phase 2	39